Abstract
The treatment of tobacco dependence in patients admitted to hospital is a priority for the National Health Service in England. We conducted an economic analysis of a pilot intervention adapted from the Ottawa Model of Smoking Cessation, implemented in a major teaching hospital in London, England.
The cost-per-patient, cost-per-quit and Incremental Cost Effectiveness Ratio were estimated for 673 patients who smoked and who received the intervention after being admitted to one of 11 acute wards between July 2020 and June 2021. Patient-level readmission costs and bed-days from six months after discharge were compared between the intervention group and a group of benchmark patients who smoked and who did not receive the intervention.
The total cost of the intervention was £178,105. On the basis of 104 patients who reported not smoking at six months, the cost-per-quit was £1712.55. Among 611 patients who were successfully matched to a benchmark cohort, re-admissions for patients in the intervention group cost £492k less than their benchmark equivalents over 21 months from January 2021 to September 2022 (£266k vs £758k), incurred 414 fewer bed days (303 vs 717), and re-admitted at a lower rate (5% vs 11%). Lower readmission rates and costs were associated with the intervention regardless of patient smoking status at six months, except among those who had opted out.
A pilot tobacco dependence treatment intervention implemented in an acute hospital setting in London demonstrated value for money through reduced readmission rates and costs among all patients who received it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Service evaluation approval was obtained from King's College Hospital NHS Hospital Trusts prior to the evaluation (reference 11641: Service evaluation and clinical audit of tobacco dependence treatment started in hospital). All individual-level data used in our study had been de-identified prior to use.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos